Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From VIB
Rare disease gene therapy play Orchard added new investors in an oversubscribed Series B raising $110m and therapeutic antibody developer Allakos raised $100m in its Series B round, while Obsidian raises $49.5m for next-generation cancer cell therapies in Series A.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2017.
Derived from Strategic Transactions, a fully searchable premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced January through February 2014.
Each month, Start-Up presents a comprehensive review of young, private life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation & reagent sectors.
- Academic and Research Institutions
- Other Names / Subsidiaries
- Flanders Institute for Biotechnology
- Oncurious NV (Joint Venture)
- Vlaams Instituut voor Biotechnologie
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.